Read by QxMD icon Read

ingenol mebutate

T Gracia-Cazaña, A Milagro, F Queipo, Y Gilaberte
Actinic keratoses are cutaneous lesions that appear as the result of the proliferation of atypical keratinocytes. These lesions are considered pre-malignant and they can progress to squamous cell carcinoma. Ingenol mebutate has been approved as an effective treatment for AK on the face and trunk. We studied the local skin reactions to this therapy. Data about local skin reactions were collected in a series of 5 patients with photographic documentation, a visual analog scale, and a ranking of satisfaction of the patient...
September 19, 2017: Dermatology Online Journal
Alberto Conde-Taboada, Bárbara Mercado, Beatriz Aranegui, Elena González-Guerra, Eduardo López-Bran
Actinic keratoses are cutaneous lesions that appear as the result of the proliferation of atypical keratinocytes. These lesions are considered pre-malignant and they can progress to squamous cell carcinoma. Ingenol mebutate has been approved as an effective treatment for AK on the face and trunk. We studied the local skin reactions to this therapy. Data about local skin reactions were collected in a series of 5 patients with photographic documentation, a visual analog scale, and a ranking of satisfaction of the patient...
September 15, 2017: Dermatology Online Journal
Stephan Alexander Braun, Erich Bünemann, Julia Baran, Bernhard Homey, Peter Arne Gerber
Recently, it has been reported that ingenol mebutate (IM) is an effective treatment option for anogenital warts (AGW), inducing fast wart necrosis within 24 hours in vivo. With regard to its mode of action, IM is thought to act both by direct cytotoxic effects and as an inducer of immunologic mechanisms. To distinguish, whether the wart necrosis is mainly caused by cytotoxic effects, or whether immune mechanisms are leading, we used time-lapse imaging to analyze IM-treated warts ex vivo over 24 hours. Ex vivo IM-treated warts, which have been detached from the immune system, did not show destructive necrosis, pointing towards a primarily immune-driven mode of action of IM in the treatment of AGW...
February 20, 2018: Experimental Dermatology
Neal D Bhatia
No abstract text is available yet for this article.
March 2018: Journal of the American Academy of Dermatology
Steven Nisticò, Ester Del Duca, Valeria Torchia, Micaela Gliozzi, Ugo Bottoni, Carolina Muscoli
Actinic keratosis (AK) is a clinical condition characterized by keratinocytic dysplastic lesions of the epidermis, affecting individuals chronically exposed to sunlight. Topical therapies allow the treatment of a whole area of affected skin and currently include diclofenac sodium gel, 5-fluorouracil cream, 5-fluorouracil and acetylsalicylic acid solution, imiquimod cream, and ingenol mebutate gel. Due to the comparable efficacy of 3% diclofenac, ingenol mebutate, and 3.75% imiquimod in treating AK multiple lesions, a pharmacoeconomic evaluation of cost-effectiveness of the three treatments was needed...
January 2018: International Journal of Immunopathology and Pharmacology
Marc Mrad, Nakhle Ayoub, Ribal Mehi
No abstract text is available yet for this article.
January 2018: JAAD Case Reports
Dong Won Lee, Hyo Hyun Ahn, Young Chul Kye, Soo Hong Seo
There are only a few anecdotal case reports about Bowen's disease (BD) treated with ingenol mebutate (IM) gel but no clinical study has been published yet. The aim of this study was to evaluate the effectiveness of IM gel in the treatment of BD and to observe the therapeutic efficacy of IM alone or IM with ablative fractional laser pretreatment. Nineteen patients with BD or squamous cell carcinoma in situ confirmed by skin biopsy were enrolled. IM was applied with 0.015% gel on facial lesions for 3 days consecutively and 0...
January 31, 2018: Journal of Dermatology
R Pampena, E Benati, S Borsari, C Bombonato, M Lombardi, M Raucci, M Mirra, A Lallas, Z Apalla, I Papadimitriou, E Moscarella, A Kyrgidis, G Argenziano, G Pellacani, C Longo
BACKGROUND: Ingenol mebutate (IngMeb) 0.015% gel is an approved field treatment option for non-hyperkeratotic non-hypertrophic actinic keratosis (AKs) of face and scalp. Efficacy of IngMeb has been assessed only on a clinical ground, in the majority of studies. Dermoscopy is a pivotal tool for the diagnosis of AK, while its role in evaluating the response to non-surgical therapies for AK has not been fully defined. OBJECTIVES: Our study aims to determine if some dermoscopic features of AK of the face and scalp areas, may independently predict the response to IngMeb therapy...
January 22, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
Y C Kim, J Y Yang, J S Yoon, S J Jo, H H Ahn, K-H Song, D-Y Lee, K-Y Chung, Y-H Won, I-H Kim
BACKGROUND: Ingenol mebutate gel is a novel, field-directed topical treatment for actinic keratosis (AK). Most pivotal studies have targeted Western populations. No clinical study has been conducted to investigate its efficacy and safety in Asian populations. OBJECTIVES: To evaluate the efficacy and safety of ingenol mebutate gel for treating AK of face/scalp and trunk/extremities in a large Asian (Korean) population. METHODS: In this multi-centre, open-label, interventional, parallel group, prospective phase 4 study (PERFECT, NCT02716714), the eligible subjects were allocated into either the face/scalp or the trunk/extremities group, according to their selected treatment area location...
January 20, 2018: British Journal of Dermatology
Orit Markowitz, Katie Wang, Amanda Levine, Michelle Schwartz, Sumeet Minhas, Eleanor Feldman, Daniel M Siegel
OBJECTIVE: To determine whether actinic keratosis and photodamaged perilesional areas (field cancerization) treated successfully with topical ingenol mebutate gel 0.015% remained clear one year later, and to treat actinic keratosis and perilesional skin not treated one year earlier. DESIGN: Single-center, single-arm, open-label extension of an original clinical study completed one year earlier. SETTING: An outpatient clinic. PARTICIPANTS: Fifteen of the original 28 study patients enrolled in and who completed the extension phase...
October 2017: Journal of Clinical and Aesthetic Dermatology
Ana M L Seca, Diana C G A Pinto
Cancer is a multistage process resulting in an uncontrolled and abrupt division of cells and is one of the leading causes of mortality. The cases reported and the predictions for the near future are unthinkable. Food and Drug Administration data showed that 40% of the approved molecules are natural compounds or inspired by them, from which, 74% are used in anticancer therapy. In fact, natural products are viewed as more biologically friendly, that is less toxic to normal cells. In this review, the most recent and successful cases of secondary metabolites, including alkaloid, diterpene, triterpene and polyphenolic type compounds, with great anticancer potential are discussed...
January 16, 2018: International Journal of Molecular Sciences
Christopher G Parker, Christian A Kuttruff, Andrea Galmozzi, Lars Jørgensen, Chien-Hung Yeh, Daniel J Hermanson, Yujia Wang, Marta Artola, Steven J McKerrall, Christopher M Josyln, Bjarne Nørremark, Georg Dünstl, Jakob Felding, Enrique Saez, Phil S Baran, Benjamin F Cravatt
The diterpenoid ester ingenol mebutate (IngMeb) is the active ingredient in the topical drug Picato, a first-in-class treatment for the precancerous skin condition actinic keratosis. IngMeb is proposed to exert its therapeutic effects through a dual mode of action involving (i) induction of cell death that is associated with mitochondrial dysfunction followed by (ii) stimulation of a local inflammatory response, at least partially driven by protein kinase C (PKC) activation. Although this therapeutic model has been well characterized, the complete set of molecular targets responsible for mediating IngMeb activity remains ill-defined...
December 27, 2017: ACS Central Science
Zarqa Ali
Background Asthma is a serious global health issue and the most prevalent chronic disorder among Danish pregnant women. Exacerbations of asthma during pregnancy have been associated with increased risk of adverse pregnancy and perinatal outcomes, and by that making asthma a potential serious medical condition during pregnancy. Monitoring of asthma every four to six weeks is recommended during pregnancy, although evidence is lacking that following this recommendation will improve pregnancy outcome and, not least, be beneficial for all pregnant women with asthma...
December 2017: Danish Medical Journal
Andrés Már Erlendsson
Non-melanoma skin cancer is the most frequently occurring cancer in Caucasians today. Incidence rates in Europe have increased steadily since the 1960s and more than tripled over the last 50 years. Despite primary preventative efforts, incidences of non-melanoma skin cancer continue to rise and development of effective chemopreventative strategies is needed. In 2013, ingenol mebutate was approved in Denmark as a new topical drug for field-directed treatment for actinic keratoses. Ingenol mebutate has a dual mechanism of action, causing initial cell death, followed by an immune activation...
November 2017: Danish Medical Journal
Efstathios Rallis, Angeliki Liakopoulou, Constantinos Christodoulopoulos
No abstract text is available yet for this article.
July 2017: Journal of Clinical and Aesthetic Dermatology
Nevena Skroza, Ilaria Proietti, Nicoletta Bernardini, Veronica Balduzzi, Alessandra Mambrin, Anna Marchesiello, Ersilia Tolino, Sara Zuber, Giuseppe La Torre, Concetta Potenza
AIM: To determine factors independently influencing response to ingenol mebutate therapy and assess efficacy on clinical setting of non-hypertrophic non-hyperkeratotic actinic keratosis (AK). METHODS: Consecutive patients affected by non-hypertrophic non-hyperkeratotic AKs of the face or scalp were enrolled to receive ingenol mebutate 0.015% gel on a selected skin area of 25 cm(2) for 3 consecutive days. Local skin reactions were calculated at each follow up visit using a validated composite score...
October 10, 2017: World Journal of Clinical Oncology
E Stockfleth, C A Harwood, C Serra Guillén, T Larsson, M L Østerdal, T Skov
BACKGROUND: Ingenol mebutate (IngMeb) and diclofenac sodium (DS) are approved treatments for actinic keratosis (AK). OBJECTIVES: Compare efficacy and safety of IngMeb 0.015% gel with DS 3% gel. METHODS: Patients with 4-8 visible, discrete AK lesions on face/scalp in a 25 cm(2) contiguous area of skin were randomised 1:1 to IngMeb once-daily for 3 consecutive days, or DS twice-daily for 90 days, following label instruction. Patients presenting with AK lesions at Week 8 following IngMeb were offered a second IngMeb course...
October 14, 2017: British Journal of Dermatology
H K Larsen, C A Banzhaf, S F Thomsen, M Gormsen, R E Schopf, M Haedersdal
BACKGROUND: Anogenital warts (AGW) can cause physical discomfort and decreased quality of life. Recent case reports suggest that ingenol mebutate gel might be an effective treatment of AGW. OBJECTIVE: To explore primarily the safety, and secondarily the efficacy of ingenol mebutate gel 0.05% in patients with AGW. METHODS: This was an exploratory, open-label, 1-arm trial of ingenol mebutate gel 0.05% administered up to 3 times to patients with AGW...
October 10, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
Douglas C Wu, Isabella Guiha, Mitchel P Goldman
BACKGROUND: Ingenol mebutate gel 0.05% once daily for two consecutive days provides high clearance rates for actinic keratosis on a 25cm(2) area of the chest. However, it may cause intense local skin responses. OBJECTIVE: The objective of this study was to determine whether a lower dose of ingenol mebutate gel 0.015% could clear actinic keratosis on the chest with acceptable tolerability and a possible beneficial effect on photodamage and cosmesis. DESIGN: This was a noncomparative, open-label study (NCT02446223)...
August 2017: Journal of Clinical and Aesthetic Dermatology
Rosa Ortega Del Olmo, Rafael Salido-Vallejo
INTRODUCTION: The aim of the study was to evaluate the results on effectiveness and safety of topical treatment for actinic keratosis (AK) with ingenol mebutate gel (IMG) in real-life conditions and to perform an analysis of the factors that may influence the treatment outcomes. MATERIALS AND METHODS: Retrospective study of patients with non-hyperkeratotic AK lesions prescribed with IMG in Spain according to clinical practice. Dermatologists reported the characteristics of patients and AK at baseline, and the findings observed up to 60 d after treatment...
November 8, 2017: Journal of Dermatological Treatment
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"